Tirzepatide

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Tirzepatide and local guidelines before prescribing.

GIP and GLP-1 receptor agonist

Mechanism

Dual GIP and GLP-1 receptor agonist.

Uses

Type 2 diabetes, obesity.

Dosing

Side effects

Nausea, vomiting, diarrhoea, constipation, pancreatitis, gallstones.

Interactions

Oral contraceptive absorption affected at initiation and dose escalation; insulin and sulfonylureas increase hypoglycaemia.

Contraindications and cautions

Pancreatitis history, medullary thyroid cancer history

Monitoring

HbA1c, weight

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

Caution with dehydration

Overdose and reversal

Supportive

Special advice

Titrate slowly; use additional contraception at starts and escalations.

More from the textbook: uses, cautions and other points
Where it is discussed in the book